Axonics Inc
NASDAQ:AXNX

Watchlist Manager
Axonics Inc Logo
Axonics Inc
NASDAQ:AXNX
Watchlist
Price: 70.98 USD 0.75%
Market Cap: 3.6B USD
Have any thoughts about
Axonics Inc?
Write Note

Operating Margin
Axonics Inc

-1.7%
Current
-16%
Average
4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1.7%
=
Operating Profit
-7.2m
/
Revenue
431.9m

Operating Margin Across Competitors

Country US
Market Cap 3.6B USD
Operating Margin
-2%
Country US
Market Cap 200.4B USD
Operating Margin
17%
Country US
Market Cap 191.7B USD
Operating Margin
26%
Country US
Market Cap 141.1B USD
Operating Margin
22%
Country US
Market Cap 134.3B USD
Operating Margin
18%
Country IE
Market Cap 104.7B USD
Operating Margin
19%
Country US
Market Cap 66.2B USD
Operating Margin
14%
Country DE
Market Cap 58.1B EUR
Operating Margin
12%
Country US
Market Cap 44.4B USD
Operating Margin
28%
Country CN
Market Cap 308.3B CNY
Operating Margin
36%
Country US
Market Cap 36.5B USD
Operating Margin
13%
No Stocks Found

Axonics Inc
Glance View

Market Cap
3.6B USD
Industry
Health Care
Economic Moat
Narrow

Axonics Inc., a prominent player in the medical technology landscape, has carved a niche for itself by focusing diligently on the development and commercialization of innovative solutions for bladder and bowel dysfunction. Founded in 2012, the company's primary product is its Sacral Neuromodulation (SNM) system, designed to treat urinary and fecal incontinence. What differentiates Axonics is its dedication to addressing a pervasive issue with an underpinning focus on patient-centric design and effective long-term treatment. Its SNM system offers users rechargeable batteries, providing a less invasive and more cost-effective solution compared to traditional systems. This technology not only addresses significant medical needs but also aligns well with a growing trend toward minimally invasive solutions in medtech. The operational model of Axonics is straightforward yet well-suited to drive profitability. Revenues primarily derive from the sales of its SNM system, which is marketed directly to healthcare providers and practitioners. This involves an intricate network of sales representatives and a hands-on approach to training medical professionals on the benefits and use of their systems, ensuring that the technology translates efficiently into patient treatment. By focusing extensively on a specific segment within the broader medical device industry, Axonics has positioned itself to capitalize on a substantial market opportunity, driven by an aging population and increasing rates of incontinence-related conditions. This strategic approach not only underscores its commitment to delivering effective healthcare solutions but also signifies its potential for sustained growth within a competitive landscape.

AXNX Intrinsic Value
33.87 USD
Overvaluation 52%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1.7%
=
Operating Profit
-7.2m
/
Revenue
431.9m
What is the Operating Margin of Axonics Inc?

Based on Axonics Inc's most recent financial statements, the company has Operating Margin of -1.7%.